Therapeutic injection of C-class CpG ODN in draining lymph node area induces potent activation of immune cells and rejection of established breast cancer in mice

被引:43
作者
Yang, Liang [1 ]
Sun, Luguo [1 ]
Wu, Xiuli [1 ]
Wang, Li [2 ]
Wei, Hongfei [1 ]
Wan, Min [1 ]
Zhang, Peiyin [1 ]
Yu, Yongli [2 ]
Wang, Liying [1 ]
机构
[1] Jilin Univ, Dept Mol Biol, Norman Bethune Coll Med Sci, Changchun 130021, Peoples R China
[2] Jilin Univ, Dept Immunol, Norman Bethune Coll Med Sci, Changchun 130021, Peoples R China
关键词
CpG ODN; Immunity; Breast cancer; Draining lymph nodes; PLASMACYTOID DENDRITIC CELLS; CD8; T-CELLS; PERIPHERAL-BLOOD; OLIGONUCLEOTIDES INDUCE; ANTITUMOR IMMUNITY; CROSS-PRESENTATION; TLR9; AGONISTS; I INTERFERON; DNA; OLIGODEOXYNUCLEOTIDE;
D O I
10.1016/j.clim.2009.01.011
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
071005 [微生物学]; 100108 [医学免疫学];
摘要
In order to develop novel CpG ODNs for the treatment of breast cancer, we have designed a series of CpG ODNs and evaluated their anti-tumor activity in a breast cancer mouse model. Interestingly, a C-class CpG ODN, designated as YW002, showed a vigorous activity on the inhibition of tumor growth in mice and completely cured some of the tumor-bearing mice through injection at tumor draining lymph node (TDLN) area. The expansion of immune cells in the TDLN and tumor and the generation of tumor specific immune memory were found associated with YW002-induced anti-tumor activity in mice. These results indicate that C-class CpG ODN could be developed into a medicament in a monotherapeutic regimen for the treatment of breast cancer through injection at TDLN area in clinic. (C) 2009 Elsevier Inc. All rights reserved.
引用
收藏
页码:426 / 437
页数:12
相关论文
共 42 条
[1]
Divergent therapeutic and immunologic effects of oligodeoxynucleotides with distinct CpG motifs [J].
Ballas, ZK ;
Krieg, AM ;
Warren, T ;
Rasmussen, W ;
Davis, HL ;
Waldschmidt, M ;
Weiner, GJ .
JOURNAL OF IMMUNOLOGY, 2001, 167 (09) :4878-4886
[2]
Anti-SARS-CoV immunity induced by a novel CpG oligodeoxynucleotide [J].
Bao, MS ;
Zhang, Y ;
Wan, M ;
Dai, L ;
Hu, XP ;
Wu, XL ;
Wang, L ;
Deng, P ;
Wang, JZ ;
Chen, JZ ;
Liu, YJ ;
Yu, YL ;
Wang, LY .
CLINICAL IMMUNOLOGY, 2006, 118 (2-3) :180-187
[3]
Phase 1 trial of a CpG oligodeoxynucleotide for patients with recurrent glioblastoma [J].
Carpentier, A ;
Laigle-Donadey, F ;
Zohar, S ;
Capelle, L ;
Behin, A ;
Tibi, A ;
Martin-Duverneuil, N ;
Sanson, M ;
Lacomblez, L ;
Taillibert, S ;
Puybasset, L ;
Van Effenterre, R ;
Delattre, JY ;
Carpentier, AF .
NEURO-ONCOLOGY, 2006, 8 (01) :60-66
[4]
Carpentier AF, 2000, CLIN CANCER RES, V6, P2469
[5]
Carpentier AF, 1999, CANCER RES, V59, P5429
[6]
Plasmacytoid dendritic cells in immunity [J].
Colonna, M ;
Trinchieri, G ;
Liu, YJ .
NATURE IMMUNOLOGY, 2004, 5 (12) :1219-1226
[7]
A CpG oligodeoxynucleotide inducing anti-coxsackie B3 virus activity in human peripheral blood mononuclear cells [J].
Cong, Zhongyi ;
Wan, Min ;
Wu, Xiuli ;
Wang, Li ;
Hu, Xiaoping ;
Yang, Fenglei ;
Bao, Musheng ;
Zhang, Xuesong ;
Chen, Jianzhu ;
Wang, Liying ;
Yu, Yongli .
FEMS IMMUNOLOGY AND MEDICAL MICROBIOLOGY, 2007, 51 (01) :26-34
[8]
Hartmann E, 2003, CANCER RES, V63, P6478
[9]
Peritumoral CpG DNA elicits a coordinated response of CD8 T cells and innate effectors to cure established tumors in a murine colon carcinoma model [J].
Heckelsmiller, K ;
Rall, K ;
Beck, S ;
Schlamp, A ;
Seiderer, J ;
Jahrsdörfer, B ;
Krug, A ;
Rothenfusser, S ;
Endres, S ;
Hartmann, G .
JOURNAL OF IMMUNOLOGY, 2002, 169 (07) :3892-3899
[10]
CpG-DNA aided cross-priming by cross-presenting B cells [J].
Heit, A ;
Huster, KM ;
Schmitz, F ;
Schiemann, M ;
Busch, DH ;
Wagner, H .
JOURNAL OF IMMUNOLOGY, 2004, 172 (03) :1501-1507